Ditchcarbon
  • Contact
  1. Organizations
  2. Novavax, Inc.
Public Profile
Pharmaceutical Preparation Manufacturing
US
updated 12 days ago

Novavax, Inc. Sustainability Profile

Company website

Novavax, Inc., a leading biotechnology company headquartered in the United States, focuses on the development of innovative vaccines to combat infectious diseases. Founded in 1987, Novavax has made significant strides in the vaccine industry, particularly with its proprietary nanoparticle technology, which enhances immune responses. The company is renowned for its COVID-19 vaccine candidate, NVX-CoV2373, which has demonstrated promising efficacy in clinical trials. Novavax's commitment to advancing vaccine development has positioned it as a key player in the global health landscape, particularly in the fight against emerging infectious diseases. With a strong emphasis on research and development, Novavax continues to expand its portfolio, aiming to address unmet medical needs worldwide.

DitchCarbon Score

How does Novavax, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

19

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

31

Industry Benchmark

Novavax, Inc.'s score of 19 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.

23%

Let us know if this data was useful to you

Novavax, Inc.'s reported carbon emissions

Novavax, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges from the company. This lack of data suggests that Novavax may not have established formal commitments to reduce its carbon footprint or may not have publicly disclosed such information. In the context of the biopharmaceutical industry, many companies are increasingly focusing on sustainability and climate action. However, without specific emissions data or reduction initiatives, it is challenging to assess Novavax's position relative to its peers in terms of climate commitments.

How Carbon Intensive is Novavax, Inc.'s Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Novavax, Inc.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is Novavax, Inc.'s Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Novavax, Inc. is in US, which has a low grid carbon intensity relative to other regions.

Novavax, Inc.'s Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

Novavax, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare Novavax, Inc.'s Emissions with Industry Peers

Astra Zeneca

GB
•
Pharmaceutical Preparation Manufacturing
Updated 10 days ago

Hookipa Biotech AG

AT
•
Pharmaceutical Preparation Manufacturing
Updated about 1 month ago

Eli Lilly and Company

GB
•
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

CP Pharmaceuticals Ltd.

GB
•
Pharmaceutical Preparation Manufacturing
Updated about 2 months ago

Sinovac Biotech Ltd.

CN
•
Pharmaceutical Preparation Manufacturing
Updated about 2 months ago

Dynavax Technologies Corporation

US
•
Pharmaceutical Preparation Manufacturing
Updated 2 months ago

Let us know if this data was useful to you

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251031.5
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy